A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research.
That goal has now come a step closer with the publication of a Phase II study showing that a reverse...
Diabetes vaccine a step closer?
A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research.
More from Alimentary/Metabolic
• By
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
• By
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
• By
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
• By
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
More from Therapy Areas
• By
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
• By
The osteogenesis imperfecta drug stumbled in a second interim analysis.
• By
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.